Literature DB >> 17302905

Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells.

K Sugiyama1, R Shirai, H Mukae, H Ishimoto, T Nagata, N Sakamoto, H Ishii, S Nakayama, K Yanagihara, Y Mizuta, S Kohno.   

Abstract

Summary The macrolide antibiotics are now well known to have anti-inflammatory effects. Because dendritic cells (DCs) orchestrate immune responses, we examined the in vitro effects of clarithromycin (CAM), azithromycin (AZM) and midecamycin (MDM) on the expression of co-stimulatory molecules and production of cytokines [interleukin (IL)-10, IL-6, interferon (IFN)-gamma, IL-12p40, tumour necrosis factor (TNF)-alpha] of murine bone marrow-derived DCs by lipopolysaccharide (LPS) stimulation. A 15-membered macrolide, AZM, and a 14-membered macrolide, CAM, significantly enhanced the intensity of a co-stimulatory molecule, CD80, on DCs but not CD86 and CD40. AZM significantly increased the production of IL-10 and CAM significantly inhibited the production of IL-6 by DCs. However, a 16-membered macrolide, MDM, did not have any significant effect on these surface markers and cytokine productions. Moreover, AZM increased IL-10 and CAM decreased IL-2 productions significantly, when naive T cells derived from spleen were co-cultured with DCs treated in advance with LPS and these macrolides. These findings suggest that 14-membered and 15-membered, but not 16-membered macrolides play as anti-inflammatory agents, at least in part, through modulating the functions of DCs. However, each macrolide affects them in different ways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302905      PMCID: PMC1810497          DOI: 10.1111/j.1365-2249.2007.03299.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86.

Authors:  A N Schweitzer; F Borriello; R C Wong; A K Abbas; A H Sharpe
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

2.  Modulatory effect of antibiotics on cytokine production by human monocytes in vitro.

Authors:  K Morikawa; H Watabe; M Araake; S Morikawa
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Current understanding of the inflammatory process in cystic fibrosis: onset and etiology.

Authors:  M W Konstan; M Berger
Journal:  Pediatr Pulmonol       Date:  1997-08

4.  Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis.

Authors:  H Mukae; J Kadota; S Kohno; S Kusano; T Morikawa; S Matsukura; K Hara
Journal:  Am J Respir Crit Care Med       Date:  1995-08       Impact factor: 21.405

5.  Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis.

Authors:  H Mukae; J Kadota; J Ashitani; H Taniguchi; H Mashimoto; S Kohno; S Matsukura
Journal:  Chest       Date:  1997-12       Impact factor: 9.410

6.  [Study on azithromycin in treatment of diffuse panbronchiolitis].

Authors:  H Kobayashi; H Takeda; S Sakayori; Y Kawakami; Y Otsuka; M Tamura; K Konishi; S Tanimoto; M Fukakusa; K Shimada
Journal:  Kansenshogaku Zasshi       Date:  1995-06

7.  Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro.

Authors:  K Sakata; H Yajima; K Tanaka; Y Sakamoto; K Yamamoto; A Yoshida; Y Dohi
Journal:  Am Rev Respir Dis       Date:  1993-10

8.  Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy.

Authors:  O Sakito; J Kadota; S Kohno; K Abe; R Shirai; K Hara
Journal:  Respiration       Date:  1996       Impact factor: 3.580

9.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

10.  Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action.

Authors:  H Takizawa; M Desaki; T Ohtoshi; T Kikutani; H Okazaki; M Sato; N Akiyama; S Shoji; K Hiramatsu; K Ito
Journal:  Biochem Biophys Res Commun       Date:  1995-05-25       Impact factor: 3.575

View more
  31 in total

1.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

2.  Azithromycin distinctively modulates classical activation of human monocytes in vitro.

Authors:  M Vrančić; M Banjanac; K Nujić; M Bosnar; T Murati; V Munić; D Stupin Polančec; D Belamarić; M J Parnham; V Eraković Haber
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

Review 4.  Graft rejection - endogenous or allogeneic?

Authors:  William R Critchley; James E Fildes
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 5.  Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.

Authors:  Itsuro Kazama
Journal:  J Physiol Sci       Date:  2014-08-06       Impact factor: 2.781

6.  The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells.

Authors:  S Iwamoto; T Kumamoto; E Azuma; M Hirayama; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

Review 7.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

8.  Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice.

Authors:  Wan C Tsai; Marc B Hershenson; Ying Zhou; Umadevi Sajjan
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

9.  Efficacy of azithromycin in preventing lethal graft-versus-host disease.

Authors:  S Iwamoto; E Azuma; T Kumamoto; M Hirayama; T Yoshida; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

10.  Azithromycin treatment increases survival of high-risk corneal allotransplants.

Authors:  Carlos A Medina; Alexander M Rowe; Hongmin Yun; Jared E Knickelbein; Kira L Lathrop; Robert L Hendricks
Journal:  Cornea       Date:  2013-05       Impact factor: 2.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.